MentalHealthDaily

Zuranolone for Depression: Rapid Efficacy & Safety in Clinical Trials (2023 Review)

by GLOOM

Zuranolone, a novel antidepressant, shows promise in treating depression, as evidenced by a recent meta-analysis. A new study investigated zuranolone’s efficacy and safety, focusing on short-term rapid antidepressant effects. Highlights: Zuranolone Effectiveness: Demonstrated significant improvement in depression severity scores compared to placebo, with notable effects by day 15. Treatment-Emergent Adverse Events (TEAEs): Increased incidence in …

SSRI-Induced Sexual Dysfunction Reversed with “Drug Holidays” on Weekends (2024 Study)

by GLOOM

Selective serotonin reuptake inhibitors (SSRIs) are a mainstay in the treatment of various mental disorders but often come with the unwelcome side effect of sexual dysfunction. This issue can significantly affect patients’ adherence to their medication regime, often leading to treatment discontinuation. A recent clinical trial offers a new perspective, suggesting that ‘drug holidays’ – …

Pharmacogenomics (PGx) for Depression: Genetic Analysis to Amplify Antidepressant Efficacy? (2023 Review)

by GLOOM

Depression, a leading cause of disability globally, often presents challenges in treatment due to the variability in individual responses to antidepressants. Pharmacogenomic (PGx) testing, an approach aligning treatment with genetic makeup, promises to tailor depression therapy more effectively. Highlights: Major Depressive Disorder (MDD) impacts a significant portion of the global population, with traditional treatments often …

Psilocybin for Major Depression in Adults (2023 Evidence Review)

by GLOOM

The emerging research into psilocybin, a classical psychedelic, reveals its significant potential in treating Major Depressive Disorder (MDD). Historically used in spiritual and shamanic practices, psilocybin’s recent clinical studies have opened new avenues in mental health treatment, challenging traditional antidepressants like SSRIs. Highlights: Psilocybin’s Historical & Clinical Relevance: A natural compound used for millennia, recent …

Esketamine Nasal Spray Effective Last Resort for Treatment-Resistant Depression (TRD)? (2023 Study)

by GLOOM

Treatment-resistant depression (TRD) represents a significant challenge in mental health care, often leaving patients and clinicians in a difficult position after traditional treatments fail. Recent studies, including a prospective, observational study at a leading medical center, have brought new hope in the form of esketamine, a novel antidepressant. Highlights: Esketamine’s Mechanism: Esketamine, the S-enantiomer of …

Analyzing Serum Biomarkers to Predict Antidepressant Efficacy in Depression (2023 Study)

by GLOOM

Depression, a complex and often debilitating mental health condition, affects millions globally. Despite advances in psychiatric medicine, finding the right treatment remains a challenge for many. A recent comprehensive study, however, is shedding light on this issue by examining the role of serum biomarkers in predicting the effectiveness of antidepressant therapy. Highlights: Innovative Approach: This …

Antidepressants & Dementia Risk in Elderly Users: SSRIs vs. TCAs (2024 Study)

by GLOOM

Recent research has uncovered connections between the use of antidepressants and the risk of developing dementia in the elderly. This complex relationship, marked by varying results and considerations, is becoming a critical area of study in geriatric medicine and mental health. In light of these findings, it is crucial to delve into the nuances of …